^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AB-101
i
Other names: AB-101, AB 101, AB101
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Arbutus
Drug class:
PD-L1 inhibitor
Related drugs:
5ms
Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. (clinicaltrials.gov)
P1, N=128, Active, not recruiting, Arbutus Biopharma Corporation | Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Apr 2026 | Trial primary completion date: Dec 2026 --> Jan 2026
Enrollment closed • Trial completion date • Trial primary completion date
|
AB-101
almost2years
Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. (clinicaltrials.gov)
P1, N=164, Recruiting, Arbutus Biopharma Corporation | Not yet recruiting --> Recruiting
Enrollment open
|
AB-101
Share via
